Abstract
Heat shock protein 90 (Hsp90) is highly conserved chaperone protein which plays vital roles in stabilization, regulation and folding of client proteins in cancer cells. Client proteins are key macromolecules for carcinogenesis and their maintenance (stabilization and protection from aggregation and misfolding) is provided by Hsp90 chaperone activity. Hsp90 allows proliferation of cancer cells by keeping misfolded client proteins in their proper functional folded form and suppresses apoptotic pathways for cancer cell survival. For this purpose, Hsp90 inhibitors have become an important growing class of antitumor agents in pharmaceutical industry. To date, numerous compounds have been tested as anticancer drugs in preclinical and clinical studies. Hsp90 inhibitors may be categorized into two main classes: natural and synthetic inhibitors. In this review, we will discuss the general properties and structure of both natural inhibitors (geldanamycin, 17-AAG, 17-DMAG, herbimycin, radicicol, novobiocin, (-)-EGCG, derrubone, gedunin, celastrol and their derivatives) and synthetic inhibitors (purine scaffold inhibitors, pyrazole scaffold inhibitors, SNX-2112, STA9090 and their derivatives) along with their therapeutic strategies in many different cancer types.
Keywords: Cancer, chaperone, client proteins, geldanamycin, Hsp90 inhibitors, Hsp90.
Current Proteomics
Title:Heat Shock Protein 90 Inhibitors in Oncology
Volume: 11 Issue: 1
Author(s): Aykut Ozgur and Yusuf Tutar
Affiliation:
Keywords: Cancer, chaperone, client proteins, geldanamycin, Hsp90 inhibitors, Hsp90.
Abstract: Heat shock protein 90 (Hsp90) is highly conserved chaperone protein which plays vital roles in stabilization, regulation and folding of client proteins in cancer cells. Client proteins are key macromolecules for carcinogenesis and their maintenance (stabilization and protection from aggregation and misfolding) is provided by Hsp90 chaperone activity. Hsp90 allows proliferation of cancer cells by keeping misfolded client proteins in their proper functional folded form and suppresses apoptotic pathways for cancer cell survival. For this purpose, Hsp90 inhibitors have become an important growing class of antitumor agents in pharmaceutical industry. To date, numerous compounds have been tested as anticancer drugs in preclinical and clinical studies. Hsp90 inhibitors may be categorized into two main classes: natural and synthetic inhibitors. In this review, we will discuss the general properties and structure of both natural inhibitors (geldanamycin, 17-AAG, 17-DMAG, herbimycin, radicicol, novobiocin, (-)-EGCG, derrubone, gedunin, celastrol and their derivatives) and synthetic inhibitors (purine scaffold inhibitors, pyrazole scaffold inhibitors, SNX-2112, STA9090 and their derivatives) along with their therapeutic strategies in many different cancer types.
Export Options
About this article
Cite this article as:
Ozgur Aykut and Tutar Yusuf, Heat Shock Protein 90 Inhibitors in Oncology, Current Proteomics 2014; 11 (1) . https://dx.doi.org/10.2174/1570164611666140415224635
DOI https://dx.doi.org/10.2174/1570164611666140415224635 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
Call for Papers in Thematic Issues
Mass spectrometry data acquisition and analysis for proteomics
The Thematic Issue on "Mass spectrometry data acquisition and analysis for proteomics" aims to explore the latest advancements and challenges in the field of proteomics through the lens of mass spectrometry. Proteomics, the large-scale study of proteins and their functions, plays a crucial role in understanding various biological processes and ...read more
Peptides: State-of-Art and Commercialisation Hurdles
The Editors of the Current Proteomics (CP) journal are highly privileged to welcome scientists to submit their scientific research and review articles to be considered for publication in the upcoming thematic issue. The topics should cover various aspects of peptides in regard to their synthetic methodologies, formulation approaches, pharmacological challenges, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medicinal Chemistry Perspective of Fused Isoxazole Derivatives
Current Topics in Medicinal Chemistry Regulation of Heat Shock Proteins by miRNAs in Human Breast Cancer
MicroRNA Editorial (Thematic Issue: Improving Cancer Clinical Research and Trials with Hispanic Populations: Training and Outreach Efforts Between Moffitt Cancer Center and the Ponce School of Medicine)
Reviews on Recent Clinical Trials Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism Gold Nanoparticle-Lignan Complexes Inhibited MCF-7 Cell Proliferation in vitro: A Novel Conjugation for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Can the Status of the Breast and Ovarian Cancer Susceptibility Gene 1 Product (BRCA1) Predict Response to Taxane-Based Cancer Therapy?
Anti-Cancer Agents in Medicinal Chemistry Evaluating Protein-protein Interaction (PPI) Networks for Diseases Pathway, Target Discovery, and Drug-design Using `In silico Pharmacology`
Current Protein & Peptide Science The Therapeutic Value of Natural Agents to Treat miRNA Targeted Breast Cancer in African-American and Caucasian-American Women
Current Drug Targets Microalgal Fatty Acids and Their Implication in Health and Disease
Mini-Reviews in Medicinal Chemistry Antitumor Carbazoles
Anti-Cancer Agents in Medicinal Chemistry Antiproliferative and Proapoptotic Effects of the TrK-inhibitor GW441756 in Human Myosarcomas and Prostatic Carcinoma
Current Signal Transduction Therapy Innovative Drug Delivery Systems for the Administration of Natural Compounds
Current Bioactive Compounds Predictive Factors of Febrile Neutropenia Induced by Anticancer Chemotherapy in the South of Tunisia
Reviews on Recent Clinical Trials Oxycodone/Naloxone in the Management of Patients with Pain and Opioid–Induced Bowel Dysfunction
Current Drug Targets Tumor Physiology and Charge Dynamics of Anticancer Drugs: Implications for Camptothecin-based Drug Development
Current Medicinal Chemistry Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry Plasminogen Activator Inhibitor with Very Long Half-life (VLHL PAI-1) can Reduce Bleeding in PAI-1-deficient Patients
Cardiovascular & Hematological Disorders-Drug Targets Disintegrins
Current Drug Targets - Cardiovascular & Hematological Disorders Synthesis and in vitro Cytotoxicity Studies of Certain Novel Heterocycles Derived from Bis 1, 2, 4-Triazoles and their DNA Damage Studies
Medicinal Chemistry Avian Cytokines - An Overview
Current Pharmaceutical Design